Adult interstitial lung diseases and their epidemiology

Sesé, Lucile; Khamis, Warda; Jeny, Florence; Uzunhan, Y.; Duchemann, Boris; Valeyre, Dominique; Annesi‐Maesano, Isabella; Nunès, Hilario

doi:10.1016/j.lpm.2020.104023

Cited by 13 publications

(9 citation statements)

References 189 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The annual incidence (3.9–7.8) and prevalence (24.2–48.3) of sarcoidosis (per 100,000 population) in the present study are like those reported from France (incidence, 4.9; prevalence, 30.2) and lie within the overall range (incidence, 0.13–17.8; prevalence, 2–160) reported previously [ 13 , 34 ]. Our annual incidence (2.1–4.3) and prevalence (5.8–11.6) of IPF (per 100,000 population) are also like those in France (incidence, 2.8; prevalence, 8.2), less than Italy and Canada, but higher than Belgium and Greece [ 5 , 10 , 13 , 35 , 36 ].…”

Section: Discussionsupporting

confidence: 89%

“…Our annual incidence (2.1–4.3) and prevalence (5.8–11.6) of IPF (per 100,000 population) are also like those in France (incidence, 2.8; prevalence, 8.2), less than Italy and Canada, but higher than Belgium and Greece [ 5 , 10 , 13 , 35 , 36 ]. The presence of CTD-ILD in our population (incidence, 1.7–3.5; prevalence, 8.5–17.0 per 100,000 population) is higher than the previously reported range (incidence, 0.07–3.3; prevalence, 0.47–12.1), owing to either an actual difference in occurrence or higher referral rates [ 34 ]. Our IPF incidence is higher but prevalence lower than CTD-ILD reflecting the shorter survival in IPF [ 37 ].…”

Section: Discussioncontrasting

confidence: 79%

See 1 more Smart Citation

Incidence, prevalence, and national burden of interstitial lung diseases in India: Estimates from two studies of 3089 subjects

et al. 2022

View full text Add to dashboard Cite

Background and objective The epidemiology of interstitial lung diseases (ILDs) in developing countries remains unknown. The objective of this study was to estimate the incidence, prevalence, and national burden of ILDs in India. Methods Data of consecutive subjects (aged >12 years) with ILDs included in a registry between March 2015 and February 2020 were analyzed retrospectively. The proportion of each ILD subtype was determined. The crude annual incidence and prevalence of ILDs for our region were estimated. Subsequently, the primary estimates of the national annual incident and prevalent burden of ILD and its subtypes were calculated. Alternative estimates for each ILD subtype were calculated using the current and a large, previous Indian study (n = 1,084). Data were analyzed using SPSS version 22 and are presented descriptively. Results A total of 2,005 subjects (mean age, 50.7 years; 47% men) were enrolled. Sarcoidosis (37.3%) was the most common ILD subtype followed by connective tissue disease (CTD)-related ILDs (19.3%), idiopathic pulmonary fibrosis (IPF, 17.0%), and hypersensitivity pneumonitis (HP, 14.4%). The crude annual incidence and prevalence of ILDs were 10.1–20.2 and 49.0–98.1, respectively per 100,000 population. The best primary estimates for the crude national burden of all ILDs, sarcoidosis, CTD-ILD, IPF, HP, and other ILDs (in thousands) were 433–867, 213–427, 75–150, 51–102, 54–109, and 39–78. The respective alternative estimates (in thousands) were sarcoidosis, 127–254; CTD-ILD, 81–162; IPF, 46–91; HP, 130–261; other ILDs, 49–98. Conclusion In contrast to developed countries, sarcoidosis and HP are the ILDs with the highest burden in India.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussioncontrasting

confidence: 79%

Incidence, prevalence, and national burden of interstitial lung diseases in India: Estimates from two studies of 3089 subjects

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The incidence and prevalence of ILDs depend on the case counting method and the geographical area. Taking ILDs as a whole, incidence is considered to be around 20-30 cases per 100 000 per year and prevalence around 60-80 cases per 100 000 [16,17]. A French exhaustive study, performed in a multi-ethnic county of Greater Paris, even found a total crude prevalence of 97.9 per 100 000 [18].…”

Section: Epidemiology and Classification Of Ildsmentioning

confidence: 99%

Cardiopulmonary exercise testing in interstitial lung diseases and the value of ventilatory efficiency

Gille

Laveneziana

2021

Eur Respir Rev

View full text Add to dashboard Cite

Interstitial lung diseases (ILDs) are diverse parenchymal pulmonary disorders, primarily characterised by alveolar and interstitial inflammation and/or fibrosis, and sharing pathophysiological similarities. Thus, patients generally harbour common respiratory symptoms, lung function abnormalities and modified exercise adaptation. The most usual and disabling complaint is exertional dyspnoea, frequently responsible for premature exercise interruption. Cardiopulmonary exercise testing (CPET) is increasingly used for the clinical assessment of patients with ILD. This is because exercise performance or dyspnoea on exertion cannot reliably be predicted by resting pulmonary function tests. CPET, therefore, provides an accurate evaluation of functional capacity on an individual basis. CPET can unmask anomalies in the integrated functions of the respiratory, cardiovascular, metabolic, peripheral muscle and neurosensory systems in ILDs. CPET uniquely provides an evaluation of all above aspects and can help clinicians shape ILD patient management. Preliminary evidence suggests that CPET may also generate valuable prognostic information in ILDs and can be used to shed light on the presence of associated pulmonary hypertension. This review aims to provide comprehensive and updated evidence concerning the clinical utility of CPET in ILD patients, with particular focus on the physiological and clinical value of ventilatory efficiency (V˙E/V˙CO2).

show abstract

“…With the widespread use of hormone therapy drugs for prostate cancer, drug safety issues, such as a serious drug‐induced interstitial lung disease (ILD), are gradually emerging. ILD, also known as diffuse parenchymal lung disease, is a group of disorders classified together because of the similar clinical, radiographic, physiological or pathological manifestations 5 . Drug‐induced ILD is serious adverse drug event, with a significant impact on patient survival 6 .…”

Section: Introductionmentioning

confidence: 99%

Analysis of adverse event of interstitial lung disease in men with prostate cancer receiving hormone therapy using the Food and Drug Administration Adverse Event Reporting System

Shen

Yin

et al. 2022

Brit J Clinical Pharma

View full text Add to dashboard Cite

Aims To investigate interstitial lung disease (ILD) in men with prostate cancer receiving hormone therapy. Methods We gathered cases diagnosed with prostate cancer based on the United States Food and Drug Administration Adverse Event Reporting System (FAERS) database from 2004 to 2020. We divided the included cases into 3 groups based on the primary suspected drugs: a hormone therapy group, a positive control group (taxanes), and a negative control group. We employed reporting odds ratio, a disproportionality method, to detect the association between ILD events and target drugs. Results We finally included a total of 85 403 cases, 69 894 cases (628 ILD event cases) in the hormone therapy group, 2302 cases (158 ILD event cases) in the positive control group and 13 207 cases (72 ILD event cases) in the negative control group. There were 394 ILD event cases (62.74%) in the hormone therapy group in Japan; 78.68% of the ILD events occurred within the first year after hormone treatment. Disproportionality analysis indicated that ILD events were significantly associated with nilutamide, flutamide, bicalutamide, goserelin, degarelix and apalutamide; the reporting odds ratios (95% confidence interval) were 32.14 (11.03–93.63), 9.93 (3.62–27.21), 8.19 (6.01–11.16), 3.74 (2.61–5.37), 2.41 (1.55–3.75) and 1.94 (1.01–3.75), respectively. Conclusion Based on this FAERS pharmacovigilance analysis, the association between ILD events and hormone therapy drugs, including bicalutamide, flutamide, nilutamide, goserelin, degarelix and apalutamide, should not be ignored, especially in the Japanese population. Lung function of prostate cancer patients should be monitored when receiving the hormone therapy drugs mentioned above, especially for the first year post medication.

show abstract

Adult interstitial lung diseases and their epidemiology

Cited by 13 publications

References 189 publications

Incidence, prevalence, and national burden of interstitial lung diseases in India: Estimates from two studies of 3089 subjects

Incidence, prevalence, and national burden of interstitial lung diseases in India: Estimates from two studies of 3089 subjects

Cardiopulmonary exercise testing in interstitial lung diseases and the value of ventilatory efficiency

Analysis of adverse event of interstitial lung disease in men with prostate cancer receiving hormone therapy using the Food and Drug Administration Adverse Event Reporting System

Contact Info

Product

Resources

About